Jiahe Biologics submitted IPO applications on the Hong Kong Stock Exchange. 3 products under development are about to submit listing applications!

On June 26th Jiahe Bio filed an application for a listing on the Hong Kong Stock Exchange, with Goldman Sachs Group Inc., JPMorgan Chase and Jefferies acting as co-sponsorsIt is reported that the company is expected to in the next 12 to 18 months to China's State Drug Administration (NMPA) will be submitted to three new drug listing applications (NDA) and a number of clinical trial applications (IND)Since its inception in 2007, Jiahe Bio's strategic focus has been focused on key therapeutic areas where there are significant unmet medical needs in oncology, autoimmune and other chronic diseasesOn June 1 this year, Jiahe Bio announced the completion of a $160 million round b financing, with existing shareholders, Gao Yu capital, continuing to lead the investment, with new investors including Temasek, China Resources Zhengda Life Sciences Fund, Haitong Kaiyuan International and Cavenham PEJiahe Bio has established research centers in Shanghai, China, and San Francisco, USA, and has established a product pipeline of 15 targeted drug candidates covering known and new biological pathwaysThe company is currently conducting more than 18 clinical trials in AsiaLerociclib (GB491): Discovered and developed by G1 Therapeutics, on June 22, Jiahe Bio has entered into a partnership with the company to have exclusive development and commercialization rights in the Asia Pacific region (excluding Japan)This is a differentiated oral CDK4/6 inhibitor that has been developed for use in combination with other targeted therapies for certain types of breast and lung cancerThe drug's initial clinical data in estrogen-receptor-positive, HER2-negative (HER2-) breast cancer patients have proved that its differences with cdK4/6 inhibitors currently available in the market have proved to be a testament to the conceptual nature of its differences in tolerance and neutrophil reductionNeutrophila is one of the main toxicities associated with CDK4/6 inhibitionCurrently, the product is conducting two Phase 1/2 clinical trialsGB221: A recombinant anti-HER-2 (epidermal growth factor receptor 2) humanized monoclonal antibody, a biosimilar drug for herceptin (qurmanifestading)Gb221 showed good safety and pharmacokinetic characteristics similar to Herceptin in a completed phase 1 single-administered drug trial for HER-2-positive breast cancer patients; NDA is expected to be submitted in China in the second half of 2020GB226: A human-derived IgG4 monoclonal antibody that targets immune cell PD-1, jiahe biohasicity has core intellectual property rightsAt present, the drug is in China into a number of phase 2 key clinical studiesJiahe Bioplan will complete the first NDA submission to NMPA for the treatment of peripheral T-cell lymphoma (PTCL) in 2020, which could make GB226 the first NdA in China to be accepted for PD-1 monotoidal for PTCLGB492 (IMSA101): For the interferon gene stimulator (Stimulator of the interferon gene, STING) agonis, Jiahe Bio plans to develop it in conjunction with GB226 to treat solid tumors In the tumor environment, STING is the immune induction of the primary media cancer cells in nate Several studies have shown that STING agonants can be used in conjunction with immunocheckpoint inhibitors (ICI) as a new immunostimulation therapy that enhances the effectiveness of cancer immunity IMSA101 is currently in the U.S in a single drug Phase 1 clinical trial in patients with solid tumors, or in combination with ICI The company plans to evaluate the application of GB492 and GB226 in china GB242: For anti-tumor necrosis factor (TNF-alpha) antibodies, Inphysemsone biosimilars are an autoimmune disease drug Jiahe Bio is currently conducting phase 3 clinical trials for the treatment of rheumatoid arthritis with GB242 and plans to submit NDA to NMPA by the second half of 2020, with plans to infer other approved indications of Inphysey sepsis GB223: Recombination anti-RANKL humanized monoanti- investigation Currently, Jiahe Bio is developing GB223 for the treatment of osteoblastoma (GCTB), and is currently conducting phase 1 dose-increased clinical trials for GCTB therapy in China At the same time, the company is launching a clinical trial of GB223 for postmenopausal osteoporosis (PMO) and plans to explore the product's potential efficacy in the broader range of osteoporosis indications The company plans to submit NDA to NMPA by the first half of 2022 according to the prospectus, Jiahe Bio applied for listing on the Hong Kong Stock Exchange, raising funds for the main purposes of the program clinical trial sand and registration preparation for GB491, core products are in progress and planned clinical trials, indications expansion, registration and filing preparation and potential commercialization, as well as other candidate drugs are being and planned clinical trials wishes Jiahe and Bio-Hong Kong Stock Exchange a smooth listing process, with the help of capital, to promote more products for the benefit of patients .